-+ 0.00%
-+ 0.00%
-+ 0.00%

Veru Publishes Presentation on Enobosarm in Older Patients With Obesity

PUBT·11/16/2026 22:26:40
Listen to the news
Veru Publishes Presentation on Enobosarm in Older Patients With Obesity
  • Veru published an Obesity Week presentation detailing a post hoc analysis of enobosarm in semaglutide-treated patients aged 65 or older.
  • Over 16 weeks, lean mass rose 0.3 kg with enobosarm 3 mg versus a 2 kg decline with placebo (p=0.0001).
  • No enobosarm recipients lost at least 10% of stair-climbing power, versus 42% on placebo, among 26 patients per arm.
  • Between-group differences in stair-climbing time and power did not reach statistical significance, with p-values of 0.056 and 0.065, respectively.
  • The presentation also outlined the fully enrolled Phase 2b PLATEAU trial, testing enobosarm 3 mg in 239 older patients over 68 weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.